As mentioned in the Q1 2017 update, it is an exciting year thus far for DiscoveryBioMed with the acquisition of a BioTek Cytation 5 anchored automated system. In order to market these new capabilities and build new relationships with potential clients and partners, DBM sent a team of delegates to both the BIO International Convention and at RESI (hosted by Life Science Nation) in San Diego this past July.
Last year at BIO 2016, DBM was invited to exhibit at the BIO Innovation Zone with other select companies that are pushing the boundaries on scientific innovation and translation to the marketplace. Last year at the BIO Investor Forum, DBM was sponsored by the NIH NIDDK to present the latest data from our Adiponectin Inducer program.
This year in an effort to further increase DBM’s reach, delegates looked outside the formal BIO convention for additional meetings and attended another conference called RESI. Between these two conventions and over the course of two and a half days, DBM’s delegates Erik Schwiebert, Lawrence Greer, and Matthew Redmann had over 35 meetings with potential clients and future partners. This volume matched the activity at last year’s BIO convention.
DiscoveryBioMed is always expanding its CRO services portfolio. However, its core focus remains tightly rooted in a humanized drug discovery philosophy – meaning utilizing the most relevant humanized cellular platform as possible, regardless of whether that process is for our clients or for our own R&D programs. If you or your company are in need of custom services, especially in renal, respiratory, dermatology and metabolic diseases areas, submit a request through our online store.